drugset
Drugs / Venetoclax
last change 10 days ago re-read 9 days ago

Venetoclax

also known as VEN · ABT-199 · GDC-0199 · Venclexta · Venclyxto · ABBVIE · ABT-0199 · C45H50CLN7O7S · +8 more

Small molecule targets BCL2, MCL1 via inhibition

Developed for
acute myeloid leukemia · chronic lymphocytic leukemia/small lymphocytic lymphoma · myelodysplastic syndrome · mantle cell lymphoma · B-cell chronic lymphocytic leukemia · chronic myelomonocytic leukemia · acute lymphoblastic leukemia · diffuse large B-cell lymphoma
+99 more · plasma cell myeloma · follicular lymphoma · non-Hodgkin lymphoma · T-cell acute lymphoblastic leukemia · B-cell acute lymphoblastic leukemia · disease related to hematopoietic stem cell transplant · marginal zone lymphoma · Richter transformation · therapy related acute myeloid leukemia and myelodysplastic syndrome · mixed phenotype acute leukemia · Waldenstrom macroglobulinemia · high grade B-cell lymphoma · T-lymphoblastic lymphoma · AL amyloidosis · hematopoietic and lymphoid cell neoplasm · leukemia · T lymphoblastic leukemia/lymphoma · acute biphenotypic leukemia · acute leukemia of ambiguous lineage · adult acute lymphoblastic leukemia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · chronic myeloid leukemia · myeloid neoplasm · refractory plasma cell neoplasm · B-cell non-Hodgkin lymphoma · Burkitt lymphoma · cancer · CD4+/CD56+ hematodermic neoplasm · precursor B-cell acute lymphoblastic leukemia · small cell lung carcinoma · acute monocytic leukemia · acute promyelocytic leukemia · breast cancer · childhood acute lymphoblastic leukemia · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · myeloproliferative neoplasm, unclassifiable · precursor lymphoblastic lymphoma/leukemia · refractory hematologic cancer · T-cell non-Hodgkin lymphoma · T-cell prolymphocytic leukemia · acute leukemia · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia with mutated NPM1 · acute myeloid leukemia, FLT3 internal tandem duplication · bilineal acute myeloid leukemia · castration-resistant prostate carcinoma · childhood acute myeloid leukemia · colorectal cancer · early T cell progenitor acute lymphoblastic leukemia · female breast carcinoma · leukemia, myeloid, accelerated-phase · lymphoblastic lymphoma · myelofibrosis · myeloid sarcoma · myeloproliferative neoplasm · neoplasm of mature B-cells · neuroblastoma · non-small cell lung carcinoma · Philadelphia-positive myelogenous leukemia · primary cutaneous T-cell lymphoma · refractory malignant neoplasm · acute erythroid leukemia · acute myeloid leukemia, CEBPA gene mutation · acute undifferentiated leukemia · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · B-cell adult acute lymphocytic leukemia · B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like · breast carcinoma by gene expression profile · breast neoplasm · core binding factor acute myeloid leukemia · diffuse large B-cell lymphoma germinal center B-cell type · diffuse large B-cell lymphoma of the central nervous system · hairy cell leukemia variant · head and neck squamous cell carcinoma · hemophagocytic syndrome · high-grade B-cell lymphoma double-hit/triple-hit · HIV infectious disease · idiopathic pulmonary fibrosis · large B-cell lymphoma · lymphoid leukemia · malignant pleural mesothelioma · MALT lymphoma · metastatic prostate carcinoma · mixed phenotype acute leukemia,T/myeloid · myelodysplastic syndrome with excess blasts · myelodysplastic/myeloproliferative neoplasm · neoplasm · phosphohydroxylysinuria · premalignant hematological system disease · primary central nervous system lymphoma · primary systemic amyloidosis · prolymphocytic leukemia · refractory precursor T-lymphoblastic lymphoma/leukemia · salivary gland adenoid cystic carcinoma · synovial sarcoma · systemic lupus erythematosus · triple-negative breast carcinoma
Investigated by
AbbVie · National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Genentech, Inc. · Institute of Hematology & Blood Diseases Hospital, China · The First Affiliated Hospital of Soochow University
+496 more · Hoffmann-La Roche · Dana-Farber Cancer Institute · First Affiliated Hospital of Zhejiang University · AstraZeneca · City of Hope Medical Center · HOVON Foundation · Ruijin Hospital · Memorial Sloan Kettering Cancer Center · Janssen Research & Development, LLC · Eli Lilly and Company · GIMEMA Foundation · German CLL Study Group · Nanfang Hospital, Southern Medical University · Pharmacyclics LLC. · Roche-Genentech · Affiliated Hospital of Nantong University · Celgene Corporation · Chinese PLA General Hospital · Dongguan People's Hospital · Jining Medical University · Karyopharm Therapeutics Inc · Oregon Health and Science University · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · St. Jude Children's Research Hospital · Suzhou Hospital of Traditional Chinese Medicine · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital with Nanjing Medical University · The Second People's Hospital of Huai'an · BeiGene · Beijing 302 Hospital · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Massachusetts General Hospital · Northern Jiangsu People's Hospital · OHSU Knight Cancer Institute · Shenzhen Second People's Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · The First Affiliated Hospital of Anhui Medical University · University of Colorado, Denver · 940 Hospital of the People's Liberation Army Joint Logistic Support Force · 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Bristol-Myers Squibb · First Affiliated Hospital of Guangxi Medical University · French Innovative Leukemia Organisation · Guangdong Second Provincial General Hospital · Guangzhou First People's Hospital · Huizhou Municipal Central Hospital · Kerry Rogers · Mayo Clinic · Medical College of Wisconsin · Montefiore Medical Center · Peter MacCallum Cancer Centre, Australia · Princess Maxima Center for Pediatric Oncology · Roche Pharma AG · Shanghai Jiao Tong University School of Medicine · Stemline Therapeutics, Inc. · Swiss Cancer Institute · The General Hospital of Western Theater Command · Yantai Yuhuangding Hospital · Zhongshan People's Hospital, Guangdong, China · Acerta Pharma BV · Fight Kids Cancer · First Hospital of China Medical University · Fujian Cancer Hospital · Gateway for Cancer Research · Groupe Francophone des Myelodysplasies · Hackensack Meridian Health · Hematology department of the 920th hospital · Huai'an First People's Hospital · IBFM · Incyte Corporation · Innovative Therapies For Children with Cancer Consortium · Jacqueline Garcia, MD · Janssen-Cilag Ltd. · Loxo Oncology, Inc. · all 502 on the full record

Regulatory milestones approvals, filings & regulatory actions · 11 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (9) US (FDA) VENCLEXTA — 2017-12-20 – 2026-05-20 fda.gov ↗
Approved EU (EMA) Venclyxto — 2016-12-04 europa.eu ↗
Approved US (FDA) VENCLEXTA — 2016-04-11 fda.gov ↗

Trials 672 · started per year

today
US approved 2016
EU approved 2016
1
1
1
7
5
13
9
17
39
48
51
54
49
80
65
87
73
68
3
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 08 trials
Phase 0 NCT07358195 Jul 2026 → Dec 2028 expected chronic renal failure syndrome, disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm Massachusetts General Hospital Not yet recruiting No outcome recorded
Phase 0 NCT07059975 Oct 2025 → Oct 2028 expected childhood acute myeloid leukemia Joanna Yi Recruiting No outcome recorded
Phase 0 NCT05553782 Nov 2023 → Apr 2029 expected head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma Brigham and Women's Hospital Recruiting No outcome recorded
Phase 0 NCT05976217 Oct 2023 → Mar 2024 idiopathic pulmonary fibrosis University of Alabama at Birmingham Completed No outcome recorded
Phase 0 NCT05386576 Jun 2022 → May 2027 expected acute lymphoblastic leukemia Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 0 NCT05528354 Jun 2022 → Dec 2025 disease related to hematopoietic stem cell transplant Zhejiang University Unknown No outcome recorded
Phase 0 NCT04161248 Sep 2020 → Dec 2026 expected B-cell non-Hodgkin lymphoma Canadian Cancer Trials Group Active not recruiting No outcome recorded
Phase 0 NCT03295240 Sep 2017 → Jan 2024 mantle cell lymphoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1154 trials · 1 met primary
Phase 1 NCT07828535 Oct 2026 → Dec 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 1 NCT07814339 Sep 2026 → Jun 2028 expected acute myeloid leukemia Rutgers, The State University of New Jersey Not yet recruiting No outcome recorded
Phase 1 NCT07713732 Aug 2026 → Aug 2030 expected malignant pleural mesothelioma, small cell lung carcinoma, synovial sarcoma Treeline Biosciences, Inc. Recruiting No outcome recorded
Phase 1 NCT07511062 Aug 2026 → Aug 2029 expected acute myeloid leukemia Northside Hospital, Inc. Not yet recruiting No outcome recorded
Phase 1 NCT07679334 Aug 2026 → Aug 2028 expected myeloproliferative neoplasm Roswell Park Cancer Institute Not yet recruiting No outcome recorded
Phase 1 NCT07513129 Jun 2026 → Dec 2029 expected T-cell acute lymphoblastic leukemia M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 1 NCT07133997 May 2026 → Jun 2028 expected B-cell acute lymphoblastic leukemia City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT06802523 Apr 2026 → Dec 2028 acute myeloid leukemia National Cancer Institute (NCI) Suspended No outcome recorded
Phase 1 NCT07481175 Apr 2026 → Jan 2030 expected — Thomas Aagaard Rasmussen Recruiting No outcome recorded
Phase 1 NCT07283094 Feb 2026 → May 2028 expected acute myeloid leukemia, myelodysplastic syndrome Montefiore Medical Center Recruiting No outcome recorded
Show all 154 trials opens the full record — a long page
Phase 1/2112 trials · 1 met primary · 2 missed
Phase 1/2 NCT07847957 Jan → Apr 2027 expected B-cell chronic lymphocytic leukemia Dana-Farber Cancer Institute Not yet recruiting No outcome recorded
Phase 1/2 NCT07175415 Oct 2026 → Oct 2031 expected T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia Princess Maxima Center for Pediatric Oncology Not yet recruiting No outcome recorded
Phase 1/2 NCT07520006 May 2026 → May 2033 expected chronic lymphocytic leukemia/small lymphocytic lymphoma Nurix Therapeutics, Inc. Not yet recruiting No outcome recorded
Phase 1/2 NCT07311746 Apr 2026 → Jan 2029 expected T-cell prolymphocytic leukemia M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT07148180 Feb 2026 → Dec 2028 expected acute myeloid leukemia Jacqueline Garcia, MD Recruiting No outcome recorded
Phase 1/2 NCT06611839 Oct 2025 → Oct 2026 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 1/2 NCT05751044 Oct 2025 → Feb 2032 expected T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia Princess Maxima Center for Pediatric Oncology Recruiting No outcome recorded
Phase 1/2 NCT05745714 Oct 2025 → Feb 2032 expected T-lymphoblastic lymphoma, acute lymphoblastic leukemia Princess Maxima Center for Pediatric Oncology Recruiting No outcome recorded
Phase 1/2 NCT07451912 Sep 2025 → Sep 2027 expected acute myeloid leukemia, CEBPA gene mutation The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 1/2 NCT06129734 Jul 2025 → Mar 2027 expected acute myeloid leukemia Benjamin Tomlinson Recruiting No outcome recorded
Show all 112 trials opens the full record — a long page
Phase 2290 trials · 5 met primary · 4 missed
Phase 2 NCT07862517 Jan → Dec 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT05554419 Jan 2027 → Dec 2030 expected therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07582159 Dec 2026 → Apr 2029 expected chronic lymphocytic leukemia/small lymphocytic lymphoma City of Hope Medical Center Not yet recruiting No outcome recorded
Phase 2 NCT07153497 Nov 2026 → Apr 2030 expected acute myeloid leukemia, myelodysplastic syndrome National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT06954987 Oct 2026 → May 2028 expected acute myeloid leukemia National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07840976 Oct 2026 → May 2028 expected B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 2 NCT07690891 Oct 2026 → Dec 2029 expected chronic lymphocytic leukemia/small lymphocytic lymphoma Medical College of Wisconsin Not yet recruiting No outcome recorded
Phase 2 NCT07734038 Oct 2026 → Dec 2027 expected chronic lymphocytic leukemia/small lymphocytic lymphoma Kerry Rogers Recruiting No outcome recorded
Phase 2 NCT07605949 Oct 2026 → Jul 2028 expected acute myeloid leukemia UNC Lineberger Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07867626 Sep 2026 → Jun 2028 expected acute myeloid leukemia Rutgers, The State University of New Jersey Not yet recruiting No outcome recorded
Show all 290 trials opens the full record — a long page
Phase 2/321 trials · 1 met primary · 1 missed
Phase 2/3 NCT07425808 Dec 2026 → Oct 2028 expected acute myeloid leukemia European Organisation for Research and Treatment of Cancer - EORTC Not yet recruiting No outcome recorded
Phase 2/3 NCT07583888 May 2026 → Aug 2027 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2/3 NCT07537257 Apr 2026 → Apr 2027 expected acute myeloid leukemia Guangdong Second Provincial General Hospital Enrolling by invitation No outcome recorded
Phase 2/3 NCT07264010 Dec 2025 → Dec 2026 expected acute myeloid leukemia Nanfang Hospital, Southern Medical University Not yet recruiting No outcome recorded
Phase 2/3 NCT07052422 Jul 2025 → Dec 2027 expected myeloid neoplasm Nanfang Hospital, Southern Medical University Not yet recruiting No outcome recorded
Phase 2/3 NCT06972641 Jun 2025 → Mar 2030 expected acute myeloid leukemia, myelodysplastic syndrome Ruijin Hospital Recruiting No outcome recorded
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT06855810 Mar 2025 → Jun 2030 expected T lymphoblastic leukemia/lymphoma, childhood acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2/3 NCT06764238 Jan 2025 → Dec 2029 expected B-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 2/3 NCT05939180 Apr 2024 → Jun 2026 overdue acute myeloid leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 348 trials · 12 met primary · 4 missed
Phase 3 NCT07407140 Apr 2026 → Feb 2029 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 3 NCT07539818 Apr 2026 → Apr 2030 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
Phase 3 NCT07469046 Apr 2026 → Mar 2028 expected acute myeloid leukemia Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 3 NCT07486479 Mar → Dec 2026 expected acute myeloid leukemia The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
Phase 3 NCT07396480 Mar 2026 → Jan 2030 expected acute myeloid leukemia, myelodysplastic syndrome First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 3 NCT07407660 Feb 2026 → Feb 2028 expected acute myeloid leukemia Peking University People's Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07082452 Sep 2025 → Sep 2030 expected B-cell chronic lymphocytic leukemia Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting No outcome recorded
Phase 3 NCT07132684 Aug 2025 → Aug 2027 expected acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 3 NCT07075016 Aug 2025 → Dec 2028 expected acute myeloid leukemia HOVON Foundation Recruiting No outcome recorded
Phase 3 NCT06852222 Jun 2025 → Jun 2029 expected acute myeloid leukemia Janssen Research & Development, LLC Recruiting No outcome recorded
Phase 44 trials
Phase 4 NCT07044687 Jul 2025 → Nov 2027 expected acute myeloid leukemia AbbVie Recruiting No outcome recorded
Phase 4 NCT06763666 Feb → Jun 2025 overdue acute myeloid leukemia Nanfang Hospital, Southern Medical University Not yet recruiting No outcome recorded
Phase 4 NCT06571825 Jul 2024 → Dec 2027 expected acute myeloid leukemia He Huang Recruiting No outcome recorded
Phase 4 NCT05144243 Jan 2022 → Mar 2026 overdue acute myeloid leukemia AbbVie Active not recruiting No outcome recorded
Phase not applicable34 trials
— NCT07632170 Nov 2026 → Oct 2027 expected myeloid neoplasm Bing Han Not yet recruiting No outcome recorded
— NCT06991920 Jun 2026 → Apr 2030 expected adult acute lymphoblastic leukemia, mixed phenotype acute leukemia Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
— NCT07521124 Jun 2026 → Jun 2029 expected acute myeloid leukemia Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Not yet recruiting No outcome recorded
— NCT07635485 Jun 2026 → May 2029 expected acute myeloid leukemia The First Affiliated Hospital of Soochow University Not yet recruiting No outcome recorded
— NCT07454226 May 2026 → Mar 2028 expected acute lymphoblastic leukemia, phosphohydroxylysinuria Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07490288 May → Jul 2026 overdue acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07493161 Apr 2026 → Mar 2028 expected B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07495631 Apr 2026 → Mar 2028 expected adult acute lymphoblastic leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT07183878 Aug 2025 → Aug 2027 expected acute myeloid leukemia, myelodysplastic syndrome First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
— NCT07187505 Jul 2025 → Jul 2027 expected acute promyelocytic leukemia Anhui Medical University Active not recruiting No outcome recorded
Phase not stated1 trial
— NCT05215405 — childhood acute lymphoblastic leukemia Kathleen Ludwig No longer available No outcome recorded
Comparator or background therapy95 trials
Phase 1 NCT07439211 Background Jul 2026 → Feb 2028 expected acute myeloid leukemia Jacqueline Garcia, MD Not yet recruiting No outcome recorded
Phase 1 NCT07617285 Background May 2026 → Dec 2027 expected acute myeloid leukemia Peking University People's Hospital Recruiting No outcome recorded
Phase 1 NCT07177079 Background Mar 2026 → Dec 2028 expected acute myeloid leukemia Kittika Poonsombudlert Recruiting No outcome recorded
Phase 1 NCT07374029 Background Feb 2026 → Oct 2027 expected acute myeloid leukemia David Avigan Recruiting No outcome recorded
Phase 1 NCT07014462 Background Sep 2025 → Jun 2029 expected acute myeloid leukemia University of Vermont Enrolling by invitation No outcome recorded

Press releases naming this drug 166 releases

DateIssuerRelease
2026-06-29 AB Science AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML ab-science.com ↗
2026-06-14 Eli Lilly and Company Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL lilly.com ↗
2026-06-12 AbbVie AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results abbvie.com ↗
2026-06-11 Syndax Pharmaceuticals Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology syndax.com ↗
2026-06-03 Kyowa Kirin, Inc. Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – kyowakirin.com ↗
2026-06-02 Kura Oncology, Inc. Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML kuraoncology.com ↗
2026-05-29 AbbVie AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia abbvie.com ↗
2026-05-14 Taiho Oncology, Inc. U.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy taiho.co.jp ↗
2026-05-13 Taiho Oncology, Inc. U.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy taihooncology.com ↗
2026-04-13 Eli Lilly and Company Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL lilly.com ↗
2026-03-23 Oryzon Genomics S.A. ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax oryzon.com ↗
2026-02-20 AstraZeneca Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting astrazeneca.com ↗
Show all 166 releases opens the full record — a long page

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 786 sources stand behind the page.

FieldValueCited text
Known as venetoclax “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗
753

“Venetoclax, the first highly selective BCL-2 inhibitor available globally, is a BH3 mimetic that selectively binds to the BCL-2 protein, displacing and releasing pro-apoptotic...” NCT05909293 ↗

“This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with...” NCT02203773 ↗

“Venetoclax 400 mg, orally, days 1-28 (the dose of Venetoclax should be adjusted according to the drug dosage instructions/guidelines when combined with CYP3A4 inhibitors); AZA:...” NCT07425782 ↗

“A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the...” NCT07643636 ↗

“This study aims to evaluate the effectiveness and safety of Venetoclax and Decitabin based conditioning regimen followed with post-HSCT Decitabin maintenance therapy in TP53...” NCT05528354 ↗

“After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to...” NCT06450145 ↗

“For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1.” NCT05025098 ↗

“Venetoclax (VEN) is a BCL-2 inhibitor that can restore activation of apoptosis in malignant cells, the survival of which often depends on dysregulation of this pathway.” NCT04609826 ↗

“Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation” NCT05870995 ↗

“This phase 1b study evaluated safety and efficacy of acalabrutinib, venetoclax, and rituximab (AVR) in treatment-naive mantle cell lymphoma (TN MCL).” PMID 38781315 ↗ Sep 2024

Show 743 more sources
Known as ABBVIE ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Known as ABT-0199 “ABT-0199” NCT05600894 ↗
Known as ABT-199 “The aim of the study is to improve long term results of R-BAC, consolidating patients with high-risk (HR) features (defined as: elevated Ki67 and/or blastoid cytology and/or...” NCT03567876 ↗
26

“This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with...” NCT02203773 ↗

“Moreover, the BCL2 antagonist venetoclax (previously GDC-0199/ABT-199), tested as a single agent in relapsed / refractory CLL patients, showed striking activity with tumor...” NCT02758665 ↗

“Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety...” PMID 27233802 ↗ May 2016

“Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)” NCT02987400 ↗

“Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL” NCT03836261 ↗

“Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)” NCT03466294 ↗

“Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)” NCT02756611 ↗

“administration of the Bcl-2 inhibitor, ABT-199 (Venetoclax), showed marked efficacy in preclinical models of IPF” NCT05976217 ↗

“Venetoclax (ABT-199/GDC-0199, VEN) is a highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor” NCT04824924 ↗

“the BCL2 inhibitor ABT199/venetoclax” PMID 35154579 ↗ Feb 2022

Show 16 more sources
Known as C45H50CLN7O7S ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Known as CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Known as GDC-0199 “Moreover, the BCL2 antagonist venetoclax (previously GDC-0199/ABT-199), tested as a single agent in relapsed / refractory CLL patients, showed striking activity with tumor...” NCT02758665 ↗
6

“Venetoclax (ABT-199/GDC-0199) is a selective, potent, first-in-class BCL-2 inhibitor that restores apoptosis in cancer cells and has demonstrated clinical efficacy in a variety...” PMID 27233802 ↗ May 2016

“A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion” NCT01889186 ↗

“Venetoclax (ABT-199/GDC-0199, VEN) is a highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor” NCT04824924 ↗

“Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie and Genentech.” PMID 34599139 ↗ Oct 2021

“[14C]ABT-199 (GDC-0199)” NCT02095574 ↗

“GDC0199” NCT05600894 ↗
Known as GDC-199 “a BCL-2 inhibitor (GDC-199, venetoclax)” NCT03276468 ↗
Known as LD-VEN “short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd)” NCT05431257 ↗
Known as RG7601 “RG7601” NCT05600894 ↗
Known as UNII-N54AIC43PW ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Known as VEN “The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN...” NCT03295240 ↗
42

“Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine...” PMID 37226312 ↗ May 2023

“This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗

“Omacetaxine mepesuccinate (OM), a semisynthetic analog of homoharringtonine, has been shown to be lethal to RUNX1 mut AML cells in vitro through reduction of MCL1 and BCL-XL,...” PMID 40979071 ↗ Jul 2025

“Functional small-molecule screening of primary acute myeloid leukemia (AML) samples identified ex vivo synergy between the JAK1/2 inhibitor, ruxolitinib (Rux), and venetoclax...” PMID 42007254 ↗ Feb 2026

“Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN...” PMID 41796974 ↗ Mar 2026

“Venetoclax (VEN), a selective BCL-2 inhibitor, in combination with a hypomethylating agent (HMA) or low-dose cytarabine, has re-defined first-line therapy for older or unfit...” NCT07814339 ↗

“• Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once...” NCT07007949 ↗

“Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored.” PMID 39919267 ↗ Apr 2025

“Venetoclax (VEN) is a BCL-2 inhibitor that can restore activation of apoptosis in malignant cells, the survival of which often depends on dysregulation of this pathway.” NCT04609826 ↗

“VEN: 400 mg, orally, days 1-28 (Venetoclax dosage must be adjusted per prescribing information/guidelines based on concomitant use of CYP3A4 inhibitors)” NCT07425782 ↗

Show 32 more sources
Known as Venclexta “Venetoclax 100 MG Oral Tablet [Venclexta]” NCT04802590 ↗
4

“Venetoclax Oral Tablet [Venclexta]” NCT05025423 ↗

“Venclexta” NCT05600894 ↗

NCT06532058 ↗

NCT05909293 ↗
Known as Venclyxto “The drug venetoclax (Venclyxto) is an inhibitor of BCL-2 (B Cell Lymphoma-2), a key factor involved in the regulation of programmed cell death.” NCT07481175 ↗
2

“Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2” NCT07214064 ↗

“Venclyxto” NCT05600894 ↗
Known as VENETOCLAX (ABT-199) ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Known as Venetoclax (ABT-199, GDC-0199) “Venetoclax (ABT-199, GDC-0199)” NCT05362942 ↗
Known as VENETOCLAXVENCLEXTAABT-199A-12314-[4-[[2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL]PIPERAZIN-1-YL]-N-[[3-NITRO-4-[[(TETRAHYDRO-2H-PYRAN-4-YL)METHYL]AMINO]PHENYL]SULFONYL]-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL3137309 ↗
Action Inhibit “the oral BCL-2 inhibitor venetoclax” PMID 34083230 ↗ Jun 2021
Modality Small molecule “venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor” PMID 27520294 ↗ Aug 2016
Route Oral “venetoclax PO QD” NCT00501826 ↗
Target BCL2 “it targets BCL2, a protein central to the survival of CLL cells.” PMID 26639348 ↗ Dec 2015